2. Signaling Pathways
  3. MAPK/ERK Pathway
    Stem Cell/Wnt
  4. ERK

ERK

Extracellular signal regulated kinases

ERK

Related Products

PDF 1.42 MB

ERKs (Extracellular-signal-regulated kinases) are widely expressed protein kinase intracellular signalling molecules that are involved in functions including the regulation of meiosis, mitosis, and postmitotic functions in differentiated cells. Many different stimuli, including growth factors, cytokines, virus infection, ligands for heterotrimeric G protein-coupled receptors, transforming agents, and carcinogens, activate the ERK pathway. In the MAPK/ERK pathway, Ras activates c-Raf, followed by mitogen-activated protein kinase kinase (abbreviated as MKK, MEK, or MAP2K) and then MAPK1/2 (below). Ras is typically activated by growth hormones through receptor tyrosine kinases and GRB2/SOS, but may also receive other signals. ERKs are known to activate many transcription factors, such as ELK1, and some downstream protein kinases. Disruption of the ERK pathway is common in cancers, especially Ras, c-Raf and receptors such as HER2.

ERK Isoform Specific Products:

ERK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-Y0078
    Cinnamyl Alcohol
    		Inhibitor 99.80%
    Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, exhibits anti-obesity, antioxidant and anti-inflammatory activities.
    Cinnamyl Alcohol
  • HY-N7067
    Revaprazan hydrochloride
    		Inhibitor 99.98%
    Revaprazan hydrochloride is reversible proton pump inhibitor. Revaprazan hydrochloride can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan hydrochloride can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan hydrochloride can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer.
    Revaprazan hydrochloride
  • HY-101446
    HIOC
    		Activator 99.94%
    HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration.
    HIOC
  • HY-B1092
    Gluconate Calcium
    		Inhibitor 98.0%
    Gluconate (D-Gluconic acid) Calcium is an orally active glucose derivative. Gluconate Calcium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate Calcium inhibits ERK phosphorylation. Gluconate Calcium has antioxidant and antiplatelet activation activities. Gluconate Calcium has antitumor activity against colorectal cancer. Gluconate Calcium improves osteoarthritis, intestinal damage and acute lung injury.
    Gluconate Calcium
  • HY-168438
    ERBB agonist-1
    		Activator 99.16%
    ERBB agonist-1 (Compound EF-1) is an agonist for ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC50 of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H2O2-induced cardiomyocyte death and Ang II (HY-13948)-induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models.
    ERBB agonist-1
  • HY-105935
    Keracyanin chloride
    		Inhibitor 99.90%
    Keracyanin chloride inhibits NF-κB/FAK/MAPK signaling pathway. Keracyanin chloride exhibits antioxidant, anti-inflammatory and hypoglycemic effects, and is orally active.
    Keracyanin chloride
  • HY-N0590
    Corynoxeine
    		Inhibitor 99.97%
    Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent ERK1/ERK2 inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.
    Corynoxeine
  • HY-114491
    Rineterkib
    		Inhibitor 99.70%
    Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
    Rineterkib
  • HY-18932
    DEL-22379
    		Inhibitor 99.69%
    DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a Kd estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC50 of ~0.5 μM.
    DEL-22379
  • HY-155417
    GPR34 receptor antagonist 3
    		Inhibitor 99.88%
    GPR34 receptor antagonist 3 (Compound 5e) is a class of GRP34 antagonists, IC50 is 0.680 μM. GPR34 receptor antagonist 3 inhibited ERK1/2 phosphorylation induced by lysophosphatidylserine in a dose-dependent way without obvious cytotoxicity. GPR34 receptor antagonist 3 shows antisensory activity in mouse neuropathic pain model .
    GPR34 receptor antagonist 3
  • HY-150700
    RLX-33
    		Modulator 99.79%
    RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome.
    RLX-33
  • HY-N0617
    Sanggenon C
    		Inhibitor 98.46%
    Sanggenon C, a flavonoid, exerts protective effects against cardiac hypertrophy and fibrosis via suppression of the calcineurin/NFAT2 pathway. Sanggenon C inhibits mitochondrial fission to induce apoptosis by blocking the ERK signaling pathway. Sanggenon C inhibits inducible nitric oxide synthase expression in RAW264.7 cells, and TNF-α-stimulated cell adhesion and VCAM-1 expression, by suppressing NF-κB activity. Sanggenon C possesses antioxidant, anti-inflammatory and antitumor activities.
    Sanggenon C
  • HY-N10521
    6'-Sialyllactose
    		Inhibitor 99.51%
    6'-Sialyllactose promotes the growth of beneficial bacteria (such as Bifidobacterium and lactobacillus) and inhibits the proliferation of harmful bacteria. 6'-Sialyllactose exhibits anti-inflammatory and anti-angiogenic activities. 6'-Sialyllactose promotes the muscle health.
    6'-Sialyllactose
  • HY-129566
    Withanolide B
    		Activator ≥99.0%
    Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects.
    Withanolide B
  • HY-N0103A
    Sophocarpine monohydrate
    		Inhibitor 99.91%
    Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage.
    Sophocarpine monohydrate
  • HY-P3513
    β-Neo-Endorphin
    		Activator 99.32%
    β-Neo-Endorphin is an endogenous opioid peptide. β-Neo-Endorphin is a hypothalamic “big” Leu-enkephalin of porcine origin. β-Neo-Endorphin shows activation of the Erk1/2, MMP-2 and MMP-9.
    β-Neo-Endorphin
  • HY-129440
    N-(p-Coumaroyl) Serotonin
    		Inhibitor 99.03%
    N-(p-Coumaroyl) Serotonin is a selective inhibitor of PDGFRβ, ERK1/2 and caspase-8 with antioxidant, anti-atherosclerotic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits glioblastoma cells (U251MG, T98G) with IC50 of 48-81 μM, while the IC50 for normal fibroblasts is 181-197 μM. N-(p-Coumaroyl) Serotonin inhibits PDGF signaling (reducing receptor phosphorylation), blocks Ca2+ influx, and induces apoptosis (activating caspase-8). N-(p-Coumaroyl) Serotonin can improve atherosclerosis and aortic wall enlargement, and can also be used in the study of glioblastoma.
    N-(p-Coumaroyl) Serotonin
  • HY-N6670
    Cefotetan
    		Activator 99.75%
    Cefotetan is a binding agent that targets human Raf1 kinase inhibitor protein (hRKIP). Cefotetan binds to hRKIP, reduces the binding space between hRKIP and Raf1 kinase, relieves hRKIP's inhibition of the Ras/Raf1/MEK/ERK signaling pathway, and enhances ERK phosphorylation. Cefotetan can be used to study diseases associated with dysregulated Ras/Raf1/MEK/ERK signaling pathways. Cefotetan is also a broad-spectrum antibacterial agent that disrupts cell wall synthesis by binding to bacterial penicillin-binding proteins (PBPs). It is used to study bacterial infections such as bone, skin, urinary tract, and lower respiratory tract.
    Cefotetan
  • HY-B1456A
    Fenoprofen
    		Activator 99.70%
    Fenoprofen (LILLY-53858) is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits cyclooxygenase (COX). Fenoprofen is a melanocortin receptors (MCRs) positive allosteric modulator (PAM). Fenoprofen also increases ERK1/2 activation in HEK293T cells. Fenoprofen has anti-arthritic activities and can be used for the study of rheumatoid arthritis and osteoarthritis.
    Fenoprofen
  • HY-12736A
    GSK143 dihydrochloride
    		Inhibitor 99.37%
    GSK143 dihydrochloride is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC50=7.1). GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice.
    GSK143 dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity
ERK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.